AI-powered research on one of the largest eye studies to date has created the most detailed maps of the retina ever produced.

The primary endpoint for the ReNEW and ReGAIN trials is the rate of change in the macular area of photoreceptor loss assessed by spectral domain-optical coherence tomography (SD-OTC) and ellipsoid ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The continued evolution of treatment protocols and ...

Fellow-KI researchers Anders Kvanta and Fredrik Lanner have been awarded a grant of SEK 10 million from the Promobilia foundation to develop a ...

Alongside these, new drug therapies are being tested to reduce retinal degeneration. With these innovations, there is growing hope for effective treatments in the future. Recent Developments in Cone ...

In the 5 patients with bilateral geographic atrophy (GA) who received a K8 implant in 1 eye, there was a mean reduction in GA lesion growth of 66% at 3 months.

Prevalence of geographic atrophy in Nordic countries and number of patients potentially eligible for intravitreal complement inhibitor treatment: A systematic review with meta-analyses and ...

The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to Beacon Therapeutics’ gene therapy, laru-zova, for treating X-linked retinitis ...

Professor Guymer's team at CERA conducts an extensive research program, collaborating with teams around the world to investigate all aspects of age-related macular degeneration. She said continued ...

While the regulator acknowledged the effect of Syfovre in slowing geographic atrophy progression, concerns were expressed over whether the drug meaningfully improved patients’ ability to see and ...

secondary to age-related macular degeneration (AMD) with an intact fovea and when central vision is threatened by GA lesion growth. SYFOVRE is the first and only approved treatment for GA in Australia ...